325 related articles for article (PubMed ID: 31933183)
1. Current and Future Molecular Targets for Acute Myeloid Leukemia Therapy.
Sami SA; Darwish NHE; Barile ANM; Mousa SA
Curr Treat Options Oncol; 2020 Jan; 21(1):3. PubMed ID: 31933183
[TBL] [Abstract][Full Text] [Related]
2. Treatment of Relapsed Acute Myeloid Leukemia.
Thol F; Ganser A
Curr Treat Options Oncol; 2020 Jun; 21(8):66. PubMed ID: 32601974
[TBL] [Abstract][Full Text] [Related]
3. Updates on targeted therapies for acute myeloid leukaemia.
Kayser S; Levis MJ
Br J Haematol; 2022 Jan; 196(2):316-328. PubMed ID: 34350585
[TBL] [Abstract][Full Text] [Related]
4. Novel Targeted Therapeutics in Acute Myeloid Leukemia: an Embarrassment of Riches.
Grieselhuber NR; Mims AS
Curr Hematol Malig Rep; 2021 Apr; 16(2):192-206. PubMed ID: 33738705
[TBL] [Abstract][Full Text] [Related]
5. Acute Myeloid Leukemia: from Mutation Profiling to Treatment Decisions.
DiNardo C; Lachowiez C
Curr Hematol Malig Rep; 2019 Oct; 14(5):386-394. PubMed ID: 31350639
[TBL] [Abstract][Full Text] [Related]
6. Acute Myeloid Leukemia Mutations and Future Mechanistic Target to Overcome Resistance.
Uddin R; Darwish NHE; Mousa SA
Curr Treat Options Oncol; 2021 Jul; 22(9):76. PubMed ID: 34213682
[TBL] [Abstract][Full Text] [Related]
7. Secondary Acute Myeloid Leukemia: A Primary Challenge of Diagnosis and Treatment.
Winer ES
Hematol Oncol Clin North Am; 2020 Apr; 34(2):449-463. PubMed ID: 32089222
[TBL] [Abstract][Full Text] [Related]
8. Treatment of Relapsed/Refractory Acute Myeloid Leukemia.
Bose P; Vachhani P; Cortes JE
Curr Treat Options Oncol; 2017 Mar; 18(3):17. PubMed ID: 28286924
[TBL] [Abstract][Full Text] [Related]
9. Midostaurin/PKC412 for the treatment of newly diagnosed FLT3 mutation-positive acute myeloid leukemia.
Luskin MR; DeAngelo DJ
Expert Rev Hematol; 2017 Dec; 10(12):1033-1045. PubMed ID: 29069942
[TBL] [Abstract][Full Text] [Related]
10. Clinical Utility of Next-Generation Sequencing in Acute Myeloid Leukemia.
Yang F; Anekpuritanang T; Press RD
Mol Diagn Ther; 2020 Feb; 24(1):1-13. PubMed ID: 31848884
[TBL] [Abstract][Full Text] [Related]
11. How Precision Medicine Is Changing Acute Myeloid Leukemia Therapy.
Heuser M; Mina A; Stein EM; Altman JK
Am Soc Clin Oncol Educ Book; 2019 Jan; 39():411-420. PubMed ID: 31099617
[TBL] [Abstract][Full Text] [Related]
12. Management of primary refractory acute myeloid leukemia in the era of targeted therapies.
McMahon CM; Perl AE
Leuk Lymphoma; 2019 Mar; 60(3):583-597. PubMed ID: 30234399
[TBL] [Abstract][Full Text] [Related]
13. The outcomes of relapsed acute myeloid leukemia in children: Results from the Japanese Pediatric Leukemia/Lymphoma Study Group AML-05R study.
Moritake H; Tanaka S; Miyamura T; Nakayama H; Shiba N; Shimada A; Terui K; Yuza Y; Koh K; Goto H; Kakuda H; Saito A; Hasegawa D; Iwamoto S; Taga T; Adachi S; Tomizawa D
Pediatr Blood Cancer; 2021 Jan; 68(1):e28736. PubMed ID: 32991072
[TBL] [Abstract][Full Text] [Related]
14. Precision medicine in acute myeloid leukemia: where are we now and what does the future hold?
Megías-Vericat JE; Martínez-Cuadrón D; Solana-Altabella A; Montesinos P
Expert Rev Hematol; 2020 Oct; 13(10):1057-1065. PubMed ID: 32869672
[TBL] [Abstract][Full Text] [Related]
15. A comprehensive review of genetic alterations and molecular targeted therapies for the implementation of personalized medicine in acute myeloid leukemia.
Kirtonia A; Pandya G; Sethi G; Pandey AK; Das BC; Garg M
J Mol Med (Berl); 2020 Aug; 98(8):1069-1091. PubMed ID: 32620999
[TBL] [Abstract][Full Text] [Related]
16. From DNA Sequencing to Clinical Trials: Finding New Targeted Drugs for Acute Myeloid Leukemia.
Yilmaz M; Daver N
Drugs; 2019 Jul; 79(11):1177-1186. PubMed ID: 31222627
[TBL] [Abstract][Full Text] [Related]
17. Acute myeloid leukemia transformed to a targetable disease.
Saleh K; Khalifeh-Saleh N; Kourie HR
Future Oncol; 2020 May; 16(14):961-972. PubMed ID: 32297538
[TBL] [Abstract][Full Text] [Related]
18. Outcome of FLT3-ITD-positive acute myeloid leukemia: impact of allogeneic stem cell transplantation and tyrosine kinase inhibitor treatment.
Fleischmann M; Schnetzke U; Schrenk KG; Schmidt V; Sayer HG; Hilgendorf I; Hochhaus A; Scholl S
J Cancer Res Clin Oncol; 2017 Feb; 143(2):337-345. PubMed ID: 27778197
[TBL] [Abstract][Full Text] [Related]
19. Are we witnessing the start of a therapeutic revolution in acute myeloid leukemia?
Bewersdorf JP; Stahl M; Zeidan AM
Leuk Lymphoma; 2019 Jun; 60(6):1354-1369. PubMed ID: 30652518
[TBL] [Abstract][Full Text] [Related]
20. Clinical and biological characteristics of acute myeloid leukemia with 20-29% blasts: a retrospective single-center study.
Mei C; Ren Y; Zhou X; Ye L; Ma L; Luo Y; Lin P; Xu W; Lu C; Yang H; Yu W; Mao L; Wei J; Jin J; Tong H
Leuk Lymphoma; 2019 May; 60(5):1136-1145. PubMed ID: 30301399
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
